UCB certolizumab Crohn’s data
This article was originally published in Pharmaceutical Approvals Monthly
UCB's Cimzia (certolizumab pegol, CDP870) showed positive efficacy results in the pivotal PRECISE 1 and 2 trials, the company says July 26. The trials are looking at certolizumab in induction and maintenance of clinical response in moderate to severe active Crohn's disease over 26 weeks. UCB plans to present the data "in more detail at the major forthcoming gastroenterology medical congresses." Cimzia also is in Phase III studies for rheumatoid arthritis...
You may also be interested in...
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.